Views & Analysis | Perspectives on pharma industry issues

Oncology

On GDF-15 neutralisation and cachexia, with CatalYm

As ESMO 2026 continues to get underway, pharmaphorum web editor Nicole Raleigh spoke with Scott Clarke, CEO of CatalYm.

Oncology

pharmaphorum podcast Episode 282 at ESMO26: Dr Chuck Link, Syncromune

ESMO26: Lowering toxicity, extending lives, with Syncromune

As the ESMO26 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast.

Oncology

Why precision biomarkers will change the future of breast ca...

Blood-based biomarkers can provide an earlier, dynamic view of what is happening inside a patient, creating an opportunity to detect changes sooner.

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Oncology

Sponsored

12 Questions with Julia Jakl

Learn more about Julia Jakl, VP and Business Unit Head, Oncology UK at GSK, in a new 12 Questions With.

Articles

Tunnah’s musings: sharing lessons in pharma social media

In his last musings of 2012, Paul Tunnah looks back on two social media workshops and the most common questions arising around this digital engagement in the pharma space. I never set out to teach people about social media and certainly don’t consider myself to be an expert. But the facts are that social media has become …

Articles

Pharma partnerships: Sanofi experimenting with a new collabo...

We get the lowdown on the first-of-its-kind pilot partnerships initiative between Sanofi and Hemarina from the man at the centre: Mohammed Charki. It’s fair to say that the pharmaceutical industry is going through major change. Gone are the days of the...

Articles

Value, big data and adaptation: the story of pharma in 2012

This year’s FT Global Pharmaceutical and Biotechnology conference focussed on value, big data, R&D innovation and adaptation for pharma, as Paul Tunnah explains. Attending the FT Global Pharmaceutical and Biotechnology conference last week it was fairly easy to tell what is keeping senior pharma execs awake at night…

Sales & Marketing

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Sales & Marketing

Building a social presence inside regulatory guardrails

In the UK, promoting prescription-only medicines to the public is prohibited by law and by the ABPI Code - social media reactions and shares included.

Digital

Sponsored

Why AI transformation is really about people

Jeff Kaminski, global head of AI and data at Axtria and a former industry analyst, discusses culture, governance, and leadership challenges around AI.

Digital